ClinicalTrials.gg
CompletedNCT01357213Updated Dec 5, 2014

Phase 1 PK Study of XOMA 3AB

A Phase 1 interventional study of XOMA 3AB and Placebo in Botulism, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-05.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a phase I, single-center, placebo-controlled, double-blinded, dose escalation study of anti-botulinum toxin monoclonal antibodies in healthy adult volunteers. Volunteers will be hospitalized in the Johns Hopkins Phase 1 unit during the infusion and until after the 24-hour blood draw. Three escalating dose cohorts of a combination of three anti-botulinum monoclonal antibodies will be evaluated. Each cohort will consist of eight volunteers in which they will receive a single intravenous infusion of active drug or placebo. Placebo will be normal saline. Volunteers will be followed for safety for up to 120 days after infusion depending on dose cohort.

Read the detailed description

This is a phase I, single-center, placebo-controlled, double-blinded, dose escalation study of anti-botulinum toxin monoclonal antibodies in healthy adult volunteers. Volunteers will be hospitalized in the Johns Hopkins Phase 1 unit during the infusion and until after the 24-hour blood draw. Three escalating dose cohorts of a combination of three anti-botulinum monoclonal antibodies will be evaluated. Each cohort will consist of eight volunteers in which they will receive a single intravenous infusion of active drug or placebo. Placebo will be normal saline. Volunteers will be followed for safety for up to 120 days after infusion depending on dose cohort.

02

Conditions studied

  • Botulism

Browse trials for

Keywords

  • Botulism, Clostridium
03

In context

Botulism

20 studies on the registry are indexed under Botulism; 3 are open to participants now.

This study's enrollment of 24 is below the median of 29 across 14 interventional studies indexed under Botulism.

Browse Botulism studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,446 studies on the registry; 179 are open to participants now.

Of its 405 completed or terminated interventional studies of FDA-regulated products, 302 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • understood and signed
  • Healthy male or healthy, non-pregnant, non-lactating female
  • Willingness to comply and be available for all protocol procedures
  • Age between 18 and 45 years, inclusive on the day of infusion
  • of \< 35
  • Blood pressure within acceptable limits (systolic blood pressure \</=140mmHg and diastolic blood pressure \</=90mmHg). If subject is receiving anti-hypertensive medications, blood pressure must be well controlled with no changes in anti-hypertensive medications for at least 3 months.
  • If the subject is female and of , negative serum pregnancy test at screening and negative urine or serum pregnancy test within 24 hours prior to infusion.
  • If the subject is female and of childbearing potential, she agrees to practice abstinence from sexual intercourse with men or use acceptable , for the duration of the study:

    • A woman is considered of childbearing potential unless (>/= 1 year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)
    • Acceptable contraception methods are restricted to effective devices (Intrauterine Contraceptive Devices (IUDs), NuvaRing®) or licensed hormonal products with use of method for a minimum of 30 days prior to vaccination, condoms with spermicidal agents, monogamous relationship with a vasectomized partner, or successful Essure placement with documented confirmation test at least 3 months after the procedure.
  • All requested screening laboratory values are within the range specified in the table, "Acceptable Ranges of Screening Labs and Vital Sign Measurements" (Appendix B).
  • Has adequate venous access for the infusion.
  • The drug screen is negative
  • Breathalyzer test is negative.

Exclusion criteria

Exclusion Criteria:

  • History of a chronic medical conditions including, but not limited to, disorders of the liver, kidney, lung, heart or nervous system, or other metabolic and /inflammatory conditions that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject such as:

    • Diabetes
    • Asthma requiring use of medication in the year before screening
    • Autoimmune disorder, such as lupus, Wegener's, rheumatoid arthritis
    • Coronary artery disease
    • History of except low-grade (squamous and basal cell) skin cancer thought to be cured
    • Chronic renal hepatic or pulmonary disease (except previous asthma which has required no treatment for the past year)
    • History of severe allergic reaction of any type to medications, bee stings, food, or environmental factors or or reaction to immunoglobulins. Severe allergic reaction is defined as any of the following:

      • Anaphylaxis
      • Urticaria
      • Angioedema
    • A marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds)
    • abnormal at screening in the judgment of the investigator
  • Positive serology results for (HIV), Surface Antigen (HBsAg), or Virus (HCV) antibodies
  • Febrile illness with temperature >37.6°C within 7 days of dosing
  • Pregnant or breastfeeding
  • Donated blood within 56 days of enrollment
  • Known allergic reactions to any of the study product components present in the formulation or in the processing, as listed in the Investigator Brochure.
  • Treatment with another drug within 30 days of dosing
  • Receipt of a monoclonal antibody at any time in the past
  • Receipt of antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin) or blood transfusion within 6 months or within 5 half-lives of the specific product given
  • Receipt of any within the previous 3 months or within 5 half-lives of the specific vaccine given
  • Receipt of any killed vaccines within the previous 1 month
  • Lack of ability to fully understand the (e.g. cannot speak or read English)
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
  • Use of H1 antihistamines or beta-blockers within 5 days of dosing.
  • Use of any of the following medications within 30 days prior to study entry or planned use during the study period:

    • immunosuppressives (except Nonsteroidal Anti-Inflammatory Drugs (NSAIDS))
    • immune modulators
    • oral (topical steroids are acceptable)
    • anti-neoplastic agents
    • any vaccine (licensed or investigational)
  • Previous exposure to botulinum toxin, receipt of antibodies against botulinum toxin, or previous treatment with equine antitoxin
  • Any previous injection or planned injection within 12 months after enrollment of botulinum toxin for cosmetic reasons, spastic dysphonia, torticollis, or any other reason
  • Any specific condition that in the judgment of the investigator precludes participation because it could affect subject safety;
  • Co-enrollment in another study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Placebo comparator
    Arm 2

    Placebo in all three cohorts

    Other: Placebo

  • Experimental
    Arm 1

    XOMA 3AB in 3 dose levels/cohorts A, B or C.

    Drug: XOMA 3AB

Interventions

  • DrugXOMA 3AB

    Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.

  • OtherPlacebo

    Normal saline 100 ml

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of XOMA 3AB: occurrence of adverse events and serious adverse events.

    Time frame: Day 0 to Day 90 and to Day 120 (depending on dose cohort).

  2. Safety and tolerability of XOMA 3AB: Changes from baseline in vital signs, physical examinations, chemistry and complete blood count with differential laboratory studies, dipstick urinalysis, and electrocardiograms.

    Time frame: Day 0, 1, 2, 3, 7, 14, 28, 42, 56, Day 90 and to 120 days (depending on dose cohort).

Secondary outcomes

  1. Immunogenicity: measuring Human anti-human antibodies (HAHA) to XOMA 3AB

    Time frame: Day 0, 28, 56, 90 and 120 days (depending on dose cohort).

  2. Pharmacokinetics of XOMA 3AB:Area under the curve to the last time with a measurable value (AUC(0-t))

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  3. Pharmacokinetics of XOMA 3AB: Volume of distribution (Vz)

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  4. Pharmacokinetics of XOMA 3AB: Total clearance (CL)

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  5. Pharmacokinetics of XOMA 3AB: Elimination half-life (t½)

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  6. Pharmacokinetics of XOMA 3AB: Elimination rate constant (gimel z)

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  7. Pharmacokinetics of XOMA 3AB: Area under the curve to infinity (AUC(inf))

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  8. Pharmacokinetics of XOMA 3AB: Time to Cmax (Tmax) measured from end of infusion

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  9. Pharmacokinetics of XOMA 3AB: Maximum plasma titer/concentration (Cmax)

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

  10. Pharmacokinetics of XOMA 3AB: Mean residence time (MRT)

    Time frame: Serially on day 0, 1, 2, 3, 7, 14, 28, 42, 56, 90 and 120 days (depending on dose cohort)

07

Study locations

1 site
  • Johns Hopkins Bayview Medical Center - Infectious Diseases
    Baltimore, Maryland 21224-2735, United States
08

References and documents

Publications

  • Nayak SU, Griffiss JM, McKenzie R, Fuchs EJ, Jurao RA, An AT, Ahene A, Tomic M, Hendrix CW, Zenilman JM. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob Agents Chemother. 2014 Sep;58(9):5047-53. doi: 10.1128/AAC.02830-14. Epub 2014 Jun 9. PubMed 24913160 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of May 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2011
First posted
May 20, 2011
Start
May 2011
Primary completionActual
May 2012
CompletionActual
May 2013
Last update
Dec 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01357213
Responsible party
Sponsor
First posted
May 20, 2011
Start date
May 2011
Primary completion
May 2012
Completion
May 2013
Last update
Dec 5, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion